Provided by Tiger Trade Technology Pte. Ltd.

Niagen Bioscience

3.21
-0.0050-0.16%
Volume:209.63K
Turnover:678.71K
Market Cap:255.26M
PE:16.86
High:3.28
Open:3.20
Low:3.20
Close:3.21
52wk High:10.52
52wk Low:2.87
Shares:79.64M
Float Shares:55.82M
Volume Ratio:0.44
T/O Rate:0.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.1901
EPS(LYR):0.2000
ROE:21.80%
ROA:5.44%
PB:3.09
PE(LYR):16.03

Loading ...

Niagen Bioscience Inc Expected to Post Earnings of 2 Cents a Share - Earnings Preview

Reuters
·
Aug 01

Niagen Bioscience announces publication on muscle epigenetic age

TIPRANKS
·
Jul 28

Niagen Bioscience Reports Analysis Finds Niagen NR Cuts Muscle Epigenetic Age by About 2.5 Years in 5-month Trial

Reuters
·
Jul 28

Niagen Bioscience (NAGE) Gets a Buy from Roth MKM

TIPRANKS
·
Jul 27

Niagen Bioscience CEO to Speak at Canaccord Genuity Growth Conference

Reuters
·
Jul 27

Niagen Bioscience to Announce Second Quarter Financial Results on August 4

Deep News
·
Jul 21

Niagen Bioscience Schedules Q2 Earnings Call After Market Close

Reuters
·
Jul 21

Press Release: Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

Dow Jones
·
Jul 21

Niagen Bioscience Names Abhijit Kale Senior Director of Global External Research

Reuters
·
Jul 16

Niagen Bioscience Appoints Abhijit Kale, Ph.d., as Senior Director of Global External Research

THOMSON REUTERS
·
Jul 16

Niagen Bioscience's NB4168 Gets US FDA Rare Pediatric Disease Tag for Ataxia Telangiectasia

MT Newswires Live
·
Jul 13

Niagen Rises After U.S., EU Rare Disease Designations for Drug Candidate

Reuters
·
Jul 13

Niagen Bioscience receives exclusive U.S. RPD, EMA OMPD for NB4168

TIPRANKS
·
Jul 13

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (rpd) Designation and European Medicines Agency Orphan Medicinal Product Designation (ompd) for Nb4168 for the Treatment of Ataxia Telangiectasia (a-t)

THOMSON REUTERS
·
Jul 13

Niagen Bioscience Launches Program to Develop Therapies for Accelerated Aging and Rare Genetic Diseases

MT Newswires Live
·
Jul 08

Niagen Bioscience launches pharmaceutical program for aging and genetic diseases

TIPRANKS
·
Jul 08

Niagen Bioscience initiated with a Buy at Freedom Broker

TIPRANKS
·
Jul 07

Niagen Bioscience Shareholders Back Board and Governance Measures

TIPRANKS
·
Jun 30

Niagen Bioscience Holds Annual Shareholder Meeting, Elects Directors

Reuters
·
Jun 30

Niagen Bioscience - up to $50 Mln of Common Stock May be Sold Under Sales Agreement Dated June 26, 2026 - SEC Filing

THOMSON REUTERS
·
Jun 29